Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator

Dehghani, Mohammad Reza and Arya, Arash and Haghjoo, Majid and Zahra, Emkanjoo and Mohammad, Alasti and Babak, Kazemi and Nikoo, Mohammad Hosein and Sadr-Ameli, Mohammad Ali (2006) Predictors of appropriate ICD therapy in patients with implantable cardioverter-defibrillator. [Journal (Paginated)]

Full text available as:

[img] HTML


Background: Understanding the predictors of appropriate implantable cardioverter defibrillator (ICD) therapy could help to better identify candidates for ICD implantation. Methods: One hundred and sixty two patients with ICD (111 with coronary artery disease [CAD] and 51 with dilated cardiomyopathy [DCM]) were included in the study. Clinical, electrocardiographic, and ICD stored data and electrograms were collected. Results: During mean follow up of 15±11 months 54 patients (33%) received ≥ 1 appropriate ICD therapy (AICDT). We used binary logistic regression analysis with forward selection method to find the potential predictors of appropriate ICD therapy after device implantation. Male gender (odds ratio [OR] = 2.76, 95% confidence interval [CI] = 1.1 – 7.1, P=0.021), DCM as underlying heart disease (OR = 4.2, 95% CI = 1.9 – 9.5, P=0.001), and QRS width > 100 ms (OR = 2.58, 95% CI = 1.2 – 5.4, P=0.010) were correlated with increased likelihood of AICDT during the follow up period. In subgroup analysis of the patients with CAD and DCM, QRS duration > 100 ms was correlated with the probability of ≥ 1 AICDT. In our patients indication of ICD implantation (primary versus secondary prevention) did not influence probability of ≥ 1 AICDT (adjusted OR = 1.66, 95% CI = 0.7 – 4.0, Mantel-Haenszel P value P=0.355.) Conclusion: QRS width could be used as an additional simple risk stratifier beyond EF to identify potential candidates who would benefit more from ICD implantation. This may have practical implications for patient selection especially in developing countries. Indication of ICD implantation (primary versus secondary prevention) did not affect the probability of ≥ 1 AICDT during the follow up period.

Item Type:Journal (Paginated)
Keywords:Implantable cardioverter-defibrillator, Appropriate ICD therapy, Coronary artery disease, Dilated cardiomyopathy
Subjects:JOURNALS > Indian Pacing and Electrophysiology Journal
ID Code:4673
Deposited By: Indian Pacing and Electrophysiology, Journal
Deposited On:06 Jan 2006
Last Modified:11 Mar 2011 08:56

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl Med. 1997; 337:1576–1583.

2. Hamilton RM, Dorian P, Gow RM, Williams WG. Five-year experience with implantable defibrillators in children. Am J Cardiol. 1996; 77:524–526.

3. Kron J, Silka MJ, Ohm OJ, Bardy G, Benditt D. Preliminary experience with nonthoracotomy implantable cardioverter defibrillators in young patients. Pacing Clin Electrophysiol. 1994; 17:26–30.

4. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl Med. 1996; 335:1933–1940.

5. Powell AC, Fuchs T, Finkelstein DM, et al. Influence of the automatic implantable cardioverter-defibrillator on the long-term prognosis of survivors of out-of-hospital cardiac death. Circulation. 1993; 88:1083–1092.

6. Rankovic V, Karha J, Passman R, Kadish AH, Goldberger JJ. Predictors of appropriate implantable cardioverter-defibrillator therapy in patients with idiopathic dilated cardiomyopathy. Am J Cardiol. 2002; 89:1072-1076.

7. Korte T, Koditz H, Niehaus M, Paul T, Tebbenjohanns J. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2004; 27:924-932.

8. Gregoratos G, Abrams J, Epstein AE, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines American College of Cardiology/American Heart Association/North American Society for Pacing and Electrophysiology Committee. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). Circulation. 2002; 106:2145-2165.

9. Credner SC, Klingenheben T, Mauss O, Sticherling C, Hohnloser SH. Electrical storm in patients with transvenous implantable cardioverterdefibrillators: Incidence, management and prognostic implications. J Am Coll Cardiol. 1998; 32:1909-1915.

10. Greene M, Newman D, Geist M, Paquette M, Heng D, Dorian P: Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular arrhythmias. Europace. 2000; 2:263- 269.

11. Dorian P, Mangat I. Role of Amiodarone in the Era of the Implantable Cardioverter Defibrillator. J Cardiovasc Electrophysiol. 2003; 14:S78-S81.

12. Arya A, Haghjoo M, Ali Sadr-Ameli M. Risk stratification for arrhythmic death after myocardial infarction: Current perspective and future direction. Int J Cardiol. 2005: In Press.

13. Kalahasti V, Nambi V, Martin DO, et al. QRS duration and prediction of mortality in patients undergoing risk stratification for ventricular arrhythmias. Am J Cardiol. 2003; 92:798-803.

14. Kalra PR, Sharma R, Shamim W, et al. Clinical characteristics and survival of patients with chronic heart failure and prolonged QRS duration. Int J Cardiol. 2002; 86:225-231.

15. Shamim W, Yousufuddin M, Cicoria M, Gibson DG, Coats AJ, Henein MY. Incremental changes in QRS duration in serial ECGs over time identify high risk elderly patients with heart failure. Heart. 2002; 88:47-51.

16. Brilakis ES, Mavrogiorgos NC, Kopecky SL, Rihal CC, Gersh BJ, Williams BA, Clements IP. Usefulness of QRS duration in the absence of bundle branch block as an early predictor of survival in non-ST elevation acute myocardial infarction. Am J Cardiol. 2002; 89:1013-1018.

17. Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy a solution to the multicenter automatic defibrillator implantation trial (MADIT) II conundrum. Circulation. 2004; 110:1885-1889.

18. Domanski MJ, Krause-Steinrauf H, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003; 9:354-363.

19. Goldstein S. Benefits of beta-blocker therapy for heart failure: weighing the evidence.

Arch Intern Med. 2002; 162:641-648.

20. Herlitz J, Dellborg M, Karlson BW, Lindqvist J, Wedel H. Long-term mortality after acute myocardial infarction in relation to prescribed dosages of a beta-blocker at hospital discharge. Cardiovasc Drugs Ther. 2000; 14:589-595.


Repository Staff Only: item control page